Autoimmune hemolytic anemia, warm type
MONDO:0019532Warm autoimmune hemolytic anemia is the most common form of autoimmune hemolytic anemia defined by the presence of warm autoantibodies against red blood cells (autoantibodies that are active at temperatures between 37-40B0C).
Also known as: Warm Autoimmune Hemolytic Anemia, wAHA, wAIHA, warm AIHA, warm antibody AIHA, warm antibody autoimmune hemolytic anaemia, warm antibody autoimmune hemolytic anemia, warm antibody hemolytic anaemia
73 clinical trials for this condition and its sub-types, 29 tagged with Autoimmune hemolytic anemia, warm type itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Experimental immune therapy for stubborn anemia shows early promise but trial stalls
Disease control Stopped earlyThis early-phase trial tested whether low doses of interleukin-2 (IL-2), a protein that helps regulate the immune system, could help people with warm autoimmune hemolytic anemia (wAHAI) whose disease did not improve with standard steroid treatment. The study planned to give four …
Phase 1/2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental drug tested for stubborn blood disorder – but trial cut short
Disease control Stopped earlyThis early-phase study tested the drug Linperlisib in just 4 adults with autoimmune hemolytic anemia (AIHA) whose disease did not improve after at least two prior treatments. The goal was to see if the drug could help control the disease by targeting a key immune pathway. However…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Promising drug for rare blood disorder trial halted early
Disease control Stopped earlyThis phase 3 study tested the drug parsaclisib in people with primary warm autoimmune hemolytic anemia, a condition where the immune system destroys red blood cells. The trial aimed to see if parsaclisib could improve hemoglobin levels and reduce fatigue compared to a placebo. Ho…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC